Synonyms: BMY-13805 | BMY13805 | Exxua® | MJ-13805 | MJ13805 | ORG-13011 | Travivo (gepirone extended-release)
gepirone is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Gepirone (BMY-13805) is a 5-HT1A receptor agonist [5].
|
|
No information available. |
Summary of Clinical Use ![]() |
Gepirone was evaluated as a treament for psychiatric conditions including major depressive disorder [4], generalised anxiety disorder and hypoactive sexual desire disorder [3] and drug dependency. The FDA approved gepirone as a treatment for major depressive disorder in September 2023. The trade name Exxua is an extended-release formulation that was previously known as Travivo. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00000189 | Gepirone vs Placebo in Treatment of Cocaine Dependence - 3 | Phase 2 Interventional | University of Pennsylvania |